Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
Recruiting · Phase 4 · NCT06941870
Conditions: Factor VIII Deficiency
At a glance
- Research payments reported, 2025
- $6,038
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 35
About the trial
- Sponsor
- Sanofi
- Tested
- Efanesoctocog alfa (drug)
- Dates
- Started 2025-09-23; completion 2027-10-25
- Results posted
- Not yet
The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximately 12 months.
From ClinicalTrials.gov, last updated 2026-11-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $6,038 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Innovative Hematology Inc $6,038
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.